CovidChloroV1, Main, Exploration, bibRecord, 000854

Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.

Identifieur interne : 000854 ( Main/Exploration ); précédent : 000853; suivant : 000855

Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.

Auteurs : Paisan Ruamviboonsuk [Thaïlande] ; Timothy Y Y. Lai [République populaire de Chine] ; Andrew Chang [Australie] ; Chi-Chun Lai [Taïwan] ; William F. Mieler [États-Unis] ; Dennis S C. Lam [République populaire de Chine]

Source :

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) [ 2162-0989 ]

RBID : pubmed:32349115

Descripteurs français

KwdFr :
- Betacoronavirus (MeSH), Chloroquine (administration et posologie), Chloroquine (toxicité), Facteurs de risque (MeSH), Humains (MeSH), Hydroxychloroquine (administration et posologie), Hydroxychloroquine (toxicité), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (traitement médicamenteux), Rétine (anatomopathologie), Rétine (effets des médicaments et des substances chimiques), Rétinopathies (induit chimiquement).
MESH :
- administration et posologie : Chloroquine, Hydroxychloroquine.
- anatomopathologie : Rétine.
- effets des médicaments et des substances chimiques : Rétine.
- induit chimiquement : Rétinopathies.
- toxicité : Chloroquine, Hydroxychloroquine.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- Betacoronavirus, Facteurs de risque, Humains, Pandémies.

English descriptors

KwdEn :
- Betacoronavirus (MeSH), COVID-19 (MeSH), Chloroquine (administration & dosage), Chloroquine (toxicity), Coronavirus Infections (drug therapy), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (toxicity), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Retina (drug effects), Retina (pathology), Retinal Diseases (chemically induced), Risk Factors (MeSH), SARS-CoV-2 (MeSH).
MESH :
- chemical , administration & dosage : Chloroquine, Hydroxychloroquine.
- chemical , toxicity : Chloroquine, Hydroxychloroquine.
- chemically induced : Retinal Diseases.
- drug effects : Retina.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- pathology : Retina.
- Betacoronavirus, COVID-19, Humans, Pandemics, Risk Factors, SARS-CoV-2.

Abstract

The proposed doses of chloroquine (CQ) and hydroxychloroquine (HCQ) for treatment of COVID-19 (1000 mg/day for 10 days, CQ; 800 mg first day then 400 mg/day for 5 days, HCQ) in many guidelines worldwide, are considerably higher than the maximum recommended daily safe doses of both agents (≤2.3 mg/kg/day, CQ; ≤5.0 mg/kg/day, HCQ) for development of retinal toxicity. Irreversible retinal damage can occur if the exposure to the safe doses is >5 years. It is not known whether exposure to high doses over a short period of time can also cause the damage. We recommend that before prescribing CQ or HCQ, history of ocular disease should be obtained to avoid the prescription if appropriate. If either agent is to be used, routine baseline ocular examination is not absolutely necessary. Patients who do not have ocular disease should also be informed about the potential risk of retinal toxicity. Both agents, however, have not yet been proven to be beneficial to COVID-19.

DOI: 10.1097/APO.0000000000000289
PubMed: 32349115
PubMed Central: PMC7227199

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001842
to stream Main, to step Curation: 001842

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.</title>
<author><name sortKey="Ruamviboonsuk, Paisan" sort="Ruamviboonsuk, Paisan" uniqKey="Ruamviboonsuk P" first="Paisan" last="Ruamviboonsuk">Paisan Ruamviboonsuk</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lai, Timothy Y Y" sort="Lai, Timothy Y Y" uniqKey="Lai T" first="Timothy Y Y" last="Lai">Timothy Y Y. Lai</name>
<affiliation wicri:level="4"><nlm:affiliation>Deparment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Deparment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong</wicri:regionArea>
<orgName type="university">Université chinoise de Hong Kong</orgName>
<placeName><settlement type="city">Sha Tin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chang, Andrew" sort="Chang, Andrew" uniqKey="Chang A" first="Andrew" last="Chang">Andrew Chang</name>
<affiliation wicri:level="1"><nlm:affiliation>Sydney Eye Hospital, Sydney University, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Sydney Eye Hospital, Sydney University, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lai, Chi Chun" sort="Lai, Chi Chun" uniqKey="Lai C" first="Chi-Chun" last="Lai">Chi-Chun Lai</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan</wicri:regionArea>
<wicri:noRegion>Taoyuan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mieler, William F" sort="Mieler, William F" uniqKey="Mieler W" first="William F" last="Mieler">William F. Mieler</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL</wicri:regionArea>
<placeName><region type="state">Illinois</region>
<settlement type="city">Chicago</settlement>
</placeName>
<orgName type="university">Université de l'Illinois à Chicago</orgName>
</affiliation>
</author>
<author><name sortKey="Lam, Dennis S C" sort="Lam, Dennis S C" uniqKey="Lam D" first="Dennis S C" last="Lam">Dennis S C. Lam</name>
<affiliation wicri:level="3"><nlm:affiliation>International Eye Research Institute of the Chinese University of Hong Kong (Shenzhen), Shenzhen, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>International Eye Research Institute of the Chinese University of Hong Kong (Shenzhen), Shenzhen</wicri:regionArea>
<placeName><settlement type="city">Shenzhen</settlement>
<region type="province">Guangdong</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>C-MER Dennis Lam Eye Centre, C-MER International Eye Care Group Limited, Hong Kong SAR, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>C-MER Dennis Lam Eye Centre, C-MER International Eye Care Group Limited, Hong Kong SAR</wicri:regionArea>
<wicri:noRegion>Hong Kong SAR</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020 Mar-Apr</date>
<idno type="RBID">pubmed:32349115</idno>
<idno type="pmid">32349115</idno>
<idno type="doi">10.1097/APO.0000000000000289</idno>
<idno type="pmc">PMC7227199</idno>
<idno type="wicri:Area/Main/Corpus">001842</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001842</idno>
<idno type="wicri:Area/Main/Curation">001842</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001842</idno>
<idno type="wicri:Area/Main/Exploration">001842</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.</title>
<author><name sortKey="Ruamviboonsuk, Paisan" sort="Ruamviboonsuk, Paisan" uniqKey="Ruamviboonsuk P" first="Paisan" last="Ruamviboonsuk">Paisan Ruamviboonsuk</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand.</nlm:affiliation>
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lai, Timothy Y Y" sort="Lai, Timothy Y Y" uniqKey="Lai T" first="Timothy Y Y" last="Lai">Timothy Y Y. Lai</name>
<affiliation wicri:level="4"><nlm:affiliation>Deparment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Deparment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong</wicri:regionArea>
<orgName type="university">Université chinoise de Hong Kong</orgName>
<placeName><settlement type="city">Sha Tin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chang, Andrew" sort="Chang, Andrew" uniqKey="Chang A" first="Andrew" last="Chang">Andrew Chang</name>
<affiliation wicri:level="1"><nlm:affiliation>Sydney Eye Hospital, Sydney University, Sydney, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Sydney Eye Hospital, Sydney University, Sydney, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lai, Chi Chun" sort="Lai, Chi Chun" uniqKey="Lai C" first="Chi-Chun" last="Lai">Chi-Chun Lai</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</nlm:affiliation>
<country xml:lang="fr">Taïwan</country>
<wicri:regionArea>Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan</wicri:regionArea>
<wicri:noRegion>Taoyuan</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mieler, William F" sort="Mieler, William F" uniqKey="Mieler W" first="William F" last="Mieler">William F. Mieler</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL</wicri:regionArea>
<placeName><region type="state">Illinois</region>
<settlement type="city">Chicago</settlement>
</placeName>
<orgName type="university">Université de l'Illinois à Chicago</orgName>
</affiliation>
</author>
<author><name sortKey="Lam, Dennis S C" sort="Lam, Dennis S C" uniqKey="Lam D" first="Dennis S C" last="Lam">Dennis S C. Lam</name>
<affiliation wicri:level="3"><nlm:affiliation>International Eye Research Institute of the Chinese University of Hong Kong (Shenzhen), Shenzhen, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>International Eye Research Institute of the Chinese University of Hong Kong (Shenzhen), Shenzhen</wicri:regionArea>
<placeName><settlement type="city">Shenzhen</settlement>
<region type="province">Guangdong</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>C-MER Dennis Lam Eye Centre, C-MER International Eye Care Group Limited, Hong Kong SAR, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>C-MER Dennis Lam Eye Centre, C-MER International Eye Care Group Limited, Hong Kong SAR</wicri:regionArea>
<wicri:noRegion>Hong Kong SAR</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)</title>
<idno type="eISSN">2162-0989</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (administration & dosage)</term>
<term>Chloroquine (toxicity)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (administration & dosage)</term>
<term>Hydroxychloroquine (toxicity)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Retina (drug effects)</term>
<term>Retina (pathology)</term>
<term>Retinal Diseases (chemically induced)</term>
<term>Risk Factors (MeSH)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (MeSH)</term>
<term>Chloroquine (administration et posologie)</term>
<term>Chloroquine (toxicité)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (administration et posologie)</term>
<term>Hydroxychloroquine (toxicité)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Rétine (anatomopathologie)</term>
<term>Rétine (effets des médicaments et des substances chimiques)</term>
<term>Rétinopathies (induit chimiquement)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Rétine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Retinal Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Retina</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Rétine</term>
</keywords>
<keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Rétinopathies</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Retina</term>
</keywords>
<keywords scheme="MESH" qualifier="toxicité" xml:lang="fr"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Risk Factors</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Facteurs de risque</term>
<term>Humains</term>
<term>Pandémies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The proposed doses of chloroquine (CQ) and hydroxychloroquine (HCQ) for treatment of COVID-19 (1000 mg/day for 10 days, CQ; 800 mg first day then 400 mg/day for 5 days, HCQ) in many guidelines worldwide, are considerably higher than the maximum recommended daily safe doses of both agents (≤2.3 mg/kg/day, CQ; ≤5.0 mg/kg/day, HCQ) for development of retinal toxicity. Irreversible retinal damage can occur if the exposure to the safe doses is >5 years. It is not known whether exposure to high doses over a short period of time can also cause the damage. We recommend that before prescribing CQ or HCQ, history of ocular disease should be obtained to avoid the prescription if appropriate. If either agent is to be used, routine baseline ocular examination is not absolutely necessary. Patients who do not have ocular disease should also be informed about the potential risk of retinal toxicity. Both agents, however, have not yet been proven to be beneficial to COVID-19.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32349115</PMID>
<DateCompleted><Year>2020</Year>
<Month>05</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2162-0989</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>9</Volume>
<Issue>2</Issue>
<PubDate><MedlineDate>2020 Mar-Apr</MedlineDate>
</PubDate>
</JournalIssue>
<Title>Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)</Title>
<ISOAbbreviation>Asia Pac J Ophthalmol (Phila)</ISOAbbreviation>
</Journal>
<ArticleTitle>Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>85-87</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1097/APO.0000000000000289</ELocationID>
<Abstract><AbstractText>The proposed doses of chloroquine (CQ) and hydroxychloroquine (HCQ) for treatment of COVID-19 (1000 mg/day for 10 days, CQ; 800 mg first day then 400 mg/day for 5 days, HCQ) in many guidelines worldwide, are considerably higher than the maximum recommended daily safe doses of both agents (≤2.3 mg/kg/day, CQ; ≤5.0 mg/kg/day, HCQ) for development of retinal toxicity. Irreversible retinal damage can occur if the exposure to the safe doses is >5 years. It is not known whether exposure to high doses over a short period of time can also cause the damage. We recommend that before prescribing CQ or HCQ, history of ocular disease should be obtained to avoid the prescription if appropriate. If either agent is to be used, routine baseline ocular examination is not absolutely necessary. Patients who do not have ocular disease should also be informed about the potential risk of retinal toxicity. Both agents, however, have not yet been proven to be beneficial to COVID-19.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ruamviboonsuk</LastName>
<ForeName>Paisan</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Ophthalmology, Rajavithi Hospital, College of Medicine, Rangsit University, Bangkok, Thailand.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lai</LastName>
<ForeName>Timothy Y Y</ForeName>
<Initials>TYY</Initials>
<AffiliationInfo><Affiliation>Deparment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chang</LastName>
<ForeName>Andrew</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Sydney Eye Hospital, Sydney University, Sydney, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lai</LastName>
<ForeName>Chi-Chun</ForeName>
<Initials>CC</Initials>
<AffiliationInfo><Affiliation>Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mieler</LastName>
<ForeName>William F</ForeName>
<Initials>WF</Initials>
<AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lam</LastName>
<ForeName>Dennis S C</ForeName>
<Initials>DSC</Initials>
<AffiliationInfo><Affiliation>International Eye Research Institute of the Chinese University of Hong Kong (Shenzhen), Shenzhen, China.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>C-MER Dennis Lam Eye Centre, C-MER International Eye Care Group Limited, Hong Kong SAR, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><CollectiveName>for Asia-Pacific Vitreo-Retina Society</CollectiveName>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Asia Pac J Ophthalmol (Phila)</MedlineTA>
<NlmUniqueID>101583622</NlmUniqueID>
<ISSNLinking>2162-0989</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Asia Pac J Ophthalmol (Phila). 2020 Jul-Aug;9(4):374</RefSource>
<PMID Version="1">32740070</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012160" MajorTopicYN="N">Retina</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012164" MajorTopicYN="N">Retinal Diseases</DescriptorName>
<QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>5</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32349115</ArticleId>
<ArticleId IdType="doi">10.1097/APO.0000000000000289</ArticleId>
<ArticleId IdType="pii">01599573-202004000-00005</ArticleId>
<ArticleId IdType="pmc">PMC7227199</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020; doi: 10.1093/jac/dkaa114.</Citation>
</Reference>
<Reference><Citation>Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; doi: 10.1093/cid/ciaa237.</Citation>
</Reference>
<Reference><Citation>Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6:16.</Citation>
</Reference>
<Reference><Citation>Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care 2020; doi: 10.1016/j.jcrc.2020.03.005.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2020.03.005</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020; doi: 10.1016/j.ijantimicag.2020.105949.</Citation>
<ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105949</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Department of Medical Services Ministry of Public Health Thailand. Thai Treatment Guideline for COVID-19. 2020. Available at: https://ddc.moph.go.th/viralpneumonia/file/g_health_care/G2_new3_1.pdf. Accessed March 26, 2020.</Citation>
</Reference>
<Reference><Citation>Vollaard A, Gieling E, Linden P van der, et al. Medicamenteuze behandelopties bij patiënten met COVID-19 (infecties met SARS-CoV-2). 2020. Available at: https://swab.nl/nl/covid-19.Accessed March 26, 2020.</Citation>
</Reference>
<Reference><Citation>Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi 2020; 43:185–188.</Citation>
</Reference>
<Reference><Citation>Institute of Tropical Medicine Antewerp, Universiteit Antwerpen, CHU Saint-Pierre, et al. Interim Clinical Guidance for Patients Suspected of/Confirmed With Covid-19 in Belgium. 2020: 1–13. Available at: https://epidemio.wiv-isp.be/ID/Documents/Covid19/COVID-19_InterimGuidelines_Treatment_ENG.pdf. Accessed March 23, 2020.</Citation>
</Reference>
<Reference><Citation>Centers for Disease Control and Prevention. Therapeutic Options for COVID-19 Patients | CDC. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html. Accessed March 23, 2020.</Citation>
</Reference>
<Reference><Citation>Nicastri E, Petrosillo N, Bartoli TA, et al. National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management. Infect Dis Rep. 2020; doi: 10.4081/idr.2020.8543.</Citation>
</Reference>
<Reference><Citation>Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, Lum F. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016; 123:1386–1394.</Citation>
</Reference>
<Reference><Citation>Yusuf IH, Foot B, Galloway J, et al. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary consensus-statement. Eye (Lond) 2018; 32:1168–1173.</Citation>
</Reference>
<Reference><Citation>Leung LS, Neal JW, Wakelee HA, Sequist LV, Marmor MF. Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy. Am J Ophthalmol 2015; 160:799–805.</Citation>
</Reference>
<Reference><Citation>Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond) 2017; 31:828–845.</Citation>
</Reference>
<Reference><Citation>Guastalegname M, Vallone A. Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment? Clin Infect Dis. 2020; doi: 10.1093/cid/ciaa321.</Citation>
</Reference>
<Reference><Citation>Walpole SC, Prieto-Merino D, Edwards P, Cleland J, Stevens G, Roberts I. The weight of nations: an estimation of adult human biomass. BMC Public Health 2012; 12:439.</Citation>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>République populaire de Chine</li>
<li>Taïwan</li>
<li>Thaïlande</li>
<li>États-Unis</li>
</country>
<region><li>Guangdong</li>
<li>Illinois</li>
</region>
<settlement><li>Chicago</li>
<li>Sha Tin</li>
<li>Shenzhen</li>
</settlement>
<orgName><li>Université chinoise de Hong Kong</li>
<li>Université de l'Illinois à Chicago</li>
</orgName>
</list>
<tree><country name="Thaïlande"><noRegion><name sortKey="Ruamviboonsuk, Paisan" sort="Ruamviboonsuk, Paisan" uniqKey="Ruamviboonsuk P" first="Paisan" last="Ruamviboonsuk">Paisan Ruamviboonsuk</name>
</noRegion>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Lai, Timothy Y Y" sort="Lai, Timothy Y Y" uniqKey="Lai T" first="Timothy Y Y" last="Lai">Timothy Y Y. Lai</name>
</noRegion>
<name sortKey="Lam, Dennis S C" sort="Lam, Dennis S C" uniqKey="Lam D" first="Dennis S C" last="Lam">Dennis S C. Lam</name>
<name sortKey="Lam, Dennis S C" sort="Lam, Dennis S C" uniqKey="Lam D" first="Dennis S C" last="Lam">Dennis S C. Lam</name>
</country>
<country name="Australie"><noRegion><name sortKey="Chang, Andrew" sort="Chang, Andrew" uniqKey="Chang A" first="Andrew" last="Chang">Andrew Chang</name>
</noRegion>
</country>
<country name="Taïwan"><noRegion><name sortKey="Lai, Chi Chun" sort="Lai, Chi Chun" uniqKey="Lai C" first="Chi-Chun" last="Lai">Chi-Chun Lai</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Illinois"><name sortKey="Mieler, William F" sort="Mieler, William F" uniqKey="Mieler W" first="William F" last="Mieler">William F. Mieler</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000854 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000854 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32349115
   |texte=   Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32349115" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.

Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki